Office room number 2014
Philip Grossen graduated at the University of Basel and received his license as pharmacist in 2013. He conducted his master thesis about the potential of rodent
Parvoviruses in Glioma therapy ("2nd and 3rd generation of oncolytical Parvovirus therapy of cancer") at the German Cancer Research Institute (DKFZ) in Heidelberg. This work was awarded with the "Amedis Förderpreis 2012". In November 2013 he joined the Pharmaceutical Technology group as a PhD student. His research is focused on the implementation of drug delivery strategies to the brain.
|Kiene, Klara; Schenk, Susanne H.; Porta, Fabiola; Ernst, Alexandra; Witzigmann, Dominik; Grossen, Philip; Huwyler, Jörg: PDMS-b-PMOXA polymersomes for hepatocyte targeting and assessment of toxicity, in: European journal of pharmaceutics and biopharmaceutics 119, 2017, S. 322-332. URL|
|Grossen, Philip; Witzigmann, Dominik; Sieber, Sandro; Huwyler, Jörg: PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application, in: Journal of Controlled Release, 2017, S. 46-60. URL|
|Sieber, Sandro; Grossen, Philip; Detampel, Pascal; Siegfried, Salome; Witigmann, Dominik; Huwyler, Jörg: Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems in vivo, in: Journal of Controlled Release 264, 2017, S. 180-191. URL|